NeuroPace (NPCE) Cash & Equivalents Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -22.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 23.57% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -7.71% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 156.03% |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn | -45.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.30% |
| Dec 31, 2025 | 61.52% |
| Sep 30, 2025 | 33.92% |
| Jun 30, 2025 | 77.96% |
| Mar 31, 2025 | 107.87% |
| Dec 31, 2024 | -25.63% |
| Sep 30, 2024 | 58.67% |
| Jun 30, 2024 | 63.51% |
| Mar 31, 2024 | 93.42% |
| Dec 31, 2023 | 173.40% |
| Sep 30, 2023 | 70.83% |
| Jun 30, 2023 | 37.76% |
| Mar 31, 2023 | -10.27% |
| Dec 31, 2022 | -65.58% |
| Sep 30, 2022 | -78.64% |
| Jun 30, 2022 | -81.75% |
| Mar 31, 2022 | -45.89% |
| Dec 31, 2021 | -27.29% |
| Sep 30, 2021 | -38.26% |
| Jun 30, 2021 | 212.50% |
| Mar 31, 2021 | 43.82% |